Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:ITRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$4.40-0.2%$5.21$3.76▼$19.35$37.98M1.2444,395 shs29,885 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-0.23%-6.38%-20.00%-12.87%-66.87%ITRMIterum Therapeutics0.00%0.00%0.00%-82.47%-97.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$4.40-0.2%$5.21$3.76▼$19.35$37.98M1.2444,395 shs29,885 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-0.23%-6.38%-20.00%-12.87%-66.87%ITRMIterum Therapeutics0.00%0.00%0.00%-82.47%-97.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.00Hold$24.50456.82% UpsideITRMIterum Therapeutics 1.67ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ATOS and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ATOSAtossa Genetics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$120.00 ➝ $24.003/30/2026ITRMIterum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/26/2026ATOSAtossa Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/AITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.21N/AN/AN/AN/A-84.91%-72.36%8/11/2026 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/ALatest ATOS and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A4.924.92ITRMIterum TherapeuticsN/A2.131.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%ITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%ITRMIterum Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableITRMIterum Therapeutics1053.29 million52.23 millionNot OptionableATOS and ITRM HeadlinesRecent News About These CompaniesHC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)March 31, 2026 | msn.comWhat's going on with Iterum Therapeutics stock Monday?March 30, 2026 | msn.comIterum files wind-up petition due to limited cash, inability to raise equityMarch 27, 2026 | reuters.comIterum Therapeutics Announces Filing of Winding Up PetitionMarch 27, 2026 | globenewswire.comIterum Therapeutics (ITRM) price target increased by 63.64% to 9.18March 27, 2026 | msn.comIterum Therapeutics Provides Business UpdateFebruary 13, 2026 | globenewswire.comIterum Therapeutics PLCJanuary 17, 2026 | barrons.comIterum Therapeutics Provides Business UpdateDecember 23, 2025 | globenewswire.comIterum Therapeutics Provides Business UpdateDecember 17, 2025 | globenewswire.comIterum Therapeutics (ITRM) price target decreased by 21.43% to 5.61December 7, 2025 | msn.comIterum Therapeutics Provides Business UpdateDecember 5, 2025 | globenewswire.comIterum Therapeutics Provides Business UpdateNovember 24, 2025 | globenewswire.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2025 Earnings Call TranscriptNovember 15, 2025 | insidermonkey.comIterum Therapeutics sees cash runway into 2Q26November 14, 2025 | msn.comIterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15MNovember 14, 2025 | msn.comIterum Therapeutics PLC (ITRM) Q3 2025 Earnings Call Highlights: Launch Success and Financial ...November 14, 2025 | finance.yahoo.comIterum Therapeutics plc (ITRM) Q3 2025 Earnings Call TranscriptNovember 14, 2025 | seekingalpha.comIterum Therapeutics Reports Third Quarter 2025 Financial ResultsNovember 14, 2025 | globenewswire.comA Glimpse of Iterum Therapeutics's Earnings PotentialNovember 14, 2025 | benzinga.comIterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025November 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATOS and ITRM Company DescriptionsAtossa Genetics NASDAQ:ATOS$4.40 -0.01 (-0.23%) Closing price 06/10/2026 04:00 PM EasternExtended Trading$4.44 +0.04 (+0.89%) As of 06/10/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Iterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 06/9/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
